tbuckley/cabot-search huggingface dataset:
Tuberculin.
Authors: Karl von Ruck
Journal: JAMA (1891)

advertised and used.Above all else, of course, he contends that the mother's milk is the food par excellence for the infant's stomach and bow¬ els.If this is not of sufficient quantity, then a prepared food may be resorted to only to fill out the deficiency in quantity.If it becomes imper¬ ative, then a prepared food may be wholly used.Condensed milk, properly diluted with rice-water or toast-water, and sterilized, has been used under his care with the best results.He strongly ad¬ vises the sterilization of all infant artificial food, and the use of the improved "feeders."The old-time nursing bottle he denounces as a thing of evil.A Viable Child at Six and One-Half Months.-Dr.Herman L. Collyer reports (Arch, of Gynecology, June, 1891) a child born before six and one half months of uterine life had been reached.The dates were well distinguished; that is, the time of conception was well ascer¬
Chymopapain Injection
Authors: W. Scott Smith
Journal: JAMA (1984)

<h3>To the Editor.—</h3> We found that the MEDICAL NEWS article entitled "Chymopapain Injection—An Often Fruitless Endeavor?"<sup>1</sup>contained useful information, but the title and some sections were misleading. We heartily agree with Dr Sypert that chymopapain is "not useful for all low back pain." This agent is specifically indicated for the treatment of patients with documented herniated lumbar intervertebral disks whose signs and symptoms have not responded to adequate period(s) of conservative therapy. Careful patient selection and proper physician training in chemonucleolysis are essential for satisfactory results. Since Food and Drug Administration approval in 1982, these points have been clearly stated in the detailed product information for Chymodiactin, Smith Laboratories' formulation of chymopapain. We also agree with Dr Whisler that achieving good results with either chemonucleolysis or laminectomy depends strongly on patient selection. In a randomized, double-blind comparison of Chymodiactin and placebo (requiring careful patient selection) published in<i>JAMA</i>,<sup>2</sup>
PHENOLTETRACHLORPHTHALEIN ESTIMATION IN THE DUODENAL CONTENTS
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Recovery of Lethally Irradiated Dogs Following Infusion of Autologous Marrow Stored at Low Temperature in Dimethyl-Sulfoxide
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reply
Authors: K. S. Ryatt, J. W. Feather, A. Mehta, J. B. Dawson, J. A. Cotterill, R. Swallow
Journal: British Journal of Dermatology (1983)

Journal Article Reply Get access K. S. Ryatt, K. S. Ryatt The General Infirmary, Leeds. Search for other works by this author on: Oxford Academic Google Scholar J. W. Feather, J. W. Feather The General Infirmary, Leeds. Search for other works by this author on: Oxford Academic Google Scholar A. Mehta, A. Mehta The General Infirmary, Leeds. Search for other works by this author on: Oxford Academic Google Scholar J. B. Dawson, J. B. Dawson The General Infirmary, Leeds. Search for other works by this author on: Oxford Academic Google Scholar J. A. Cotterill, J. A. Cotterill The General Infirmary, Leeds. Search for other works by this author on: Oxford Academic Google Scholar R. Swallow R. Swallow The General Infirmary, Leeds. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 108, Issue 2, 1 February 1983, Page 251, https://doi.org/10.1111/j.1365-2133.1983.tb00073.x Published: 01 February 1983
Music Lessons
Authors: Justine V. Cohen
Journal: Annals of Internal Medicine (2011)

Letters2 August 2011Music LessonsJustine V. Cohen, DOJustine V. Cohen, DOFrom Pennsylvania Hospital, University of Pennsylvania Health System, Philadelphia, PA 19107.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-155-3-201108020-00026 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:I applaud Davidoff's keen inference that musicians can teach doctors (1). Parallels between music and medicine run deep. Before my medical journey began, I was a professional oboist. I received undergraduate and graduate musical training at esteemed institutions and spent my summers at music festivals, where I had the good fortune to play with some of the world's greatest musicians.Music continues to shape my consciousness as a physician in all of the overlapping aspects that Davidoff astutely identifies. Perhaps the most important “lesson” for me derives from the impact of practicing music and what this has ...Reference1. Davidoff F. Music lessons: what musicians can teach doctors (and other health professionals). Ann Intern Med. 2011;154:426-9. [PMID: 21403078] LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Pennsylvania Hospital, University of Pennsylvania Health System, Philadelphia, PA 19107.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoMusic Lessons: What Musicians Can Teach Doctors (and Other Health Professionals) Frank Davidoff Music Lessons Ayodele Odutayo and Rashida Williams Metrics 2 August 2011Volume 155, Issue 3Page: 206-207KeywordsConflicts of interestConsciousnessGraduate medical educationHealth careUndergraduatesVision ePublished: 2 August 2011 Issue Published: 2 August 2011 Copyright & PermissionsCopyright © 2011 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
A study of various tests to detect asymptomatic urinary tract infections in an obstetric population
Authors: J. W. Bachman
Journal: JAMA (1993)

<h3>Objective.</h3> —To compare rapid screening techniques for detecting asymptomatic urinary tract infections (AUTIs) in pregnant women. <h3>Design.</h3> —Comparison of results of the screening tests of urinalysis, urine dipstick, and Gram's staining with the results of standard urine culture at an initial prenatal visit. In follow-up visits, urine dipstick testing was compared with urinalysis. <h3>Setting.</h3> —Departments of Family Medicine and Obstetrics and Gynecology, Mayo Clinic, Rochester, Minn. <h3>Patients.</h3> —Pregnant women (1047) from the local community were screened for AUTI on initial and follow-up visits. <h3>Methods.</h3> —Initial prenatal urine was tested by using urine dipstick testing, urinalysis, Gram's staining, and urine culture. At each follow-up visit, urine specimens were tested by using urine dipstick and urinalysis. <h3>Main Outcome Measures.</h3> —Sensitivity and specificity, incremental patient costs, and clinical outcomes were used to assess the effectiveness of the techniques. <h3>Results.</h3> —On initial visits, rapid screening tests for AUTI in pregnant women revealed the following: Gram's staining identified 22 of 24 patients with AUTI (sensitivity, 91.7%; specificity, 89.2%); urine dipstick, 12 of 24 (sensitivity, 50.0%; specificity, 96.9%); and urinalysis with presence of leukocytes, six of 24 (sensitivity, 25.0%; specificity, 99.0%). In follow-up visits, urine dipstick tests detected 19 infections and urinalysis, three (positive predictive value, 5% compared with 3%). <h3>Conclusions.</h3> —Urine dipstick testing for nitrites identified half of all patients with urinary tract infections and was superior to urinalysis on follow-up visits. Although Gram's staining is more expensive, it was more accurate for AUTI than urinalysis or urine dipstick test for nitrites. Urinalysis was never the test of choice because it was more expensive and detected fewer positive cultures. Leukocyte measurement correlated poorly with AUTI. (<i>JAMA</i>. 1993;270:1971-1974)
MicroRNA-206 expression is down-regulated in estrogen receptor a-positive human breast cancer.
Authors: N Kondo, T Toyama, H Sugiura, Y Fujii, H Yamashita
Journal: Cancer Research (2009)

Abstract Abstract #3042 There are large-scale molecular differences between estrogen receptor (ER)-positive and ER-negative breast cancers. ERa is essential for estrogen-dependent growth, and its level of expression is a crucial determinant of response to endocrine therapy and prognosis in ER-positive breast cancer. Multiple mechanisms involved in altering ERa gene expression in breast cancer have been identified, including ERa gene amplification as well as transcriptional silencing by DNA methylation of CpG islands within the ERa promoter and mutations within the open reading frame of ERa. However, expression levels of ERa in breast cancer tissues differ widely among patients, and frequently change during disease progression and in response to systemic therapies. Recent evidence has shown that microRNA (miRNA) mutations or mis-expression correlate with various human cancers, and miR-206 is reported to decrease endogenous ERa mRNA and protein levels in human MCF-7 breast cancer cells via two specific target sites within the 3'-untranslated region of the human ERa transcript. In this study, we show that miR-206 expression is markedly decreased in ERa-positive breast cancer tissues assayed by quantitative RT-PCR analysis. We observe that miR-206 expression is inversely correlated with ERa but not ERb mRNA expression and the expression levels of miR-206 are gradually decreased as the score for ERa protein expression increases in breast cancer tissues. Moreover, transfection experiments revealed that introduction of miR-206 into estrogen-dependent MCF-7 cells inhibits cell growth and induces a dose-dependent repression of ERa mRNA levels. Transfection with miR-206 produces a dose-dependent decrease of mRNA expression of ERa-target genes, such as progesterone receptor, cyclin D1 and pS2 in MCF-7 cells. Our results suggest that miR-206 is a key factor for the regulation of ERa expression in development and progression of human breast cancer and could be a novel candidate for endocrine therapy that targets only ERa. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 3042.
Errata
Journal: BMJ (1842)

The tuft referred to was probably the source of the heemorrhage, and from its peculiar situation had ob- structed the free ingress of the urine; this excited local muscular efforts, which mechanically congested the part, and kept up the condition of hEemorrhage.Fatal hwmaturia under such circumstances must be very rare, and correct diagnosis impossible.The complete absence of vesical symptoms is worthy of notice; the renal symptoms were evidently dependant on distension.
Human hepatic stimulator substance: A product of gene expression of human fetal liver tissue
Authors: F He
Journal: Hepatology (1993)

Cloning of human hepatic stimulator substance requires clarification of whether the substance is the product of gene expression of liver cells. In this article the translation experiment in Xenopus laevis oocytes indicates that poly (A)+ messenger RNA of human fetal liver cells could conduct the biosynthesis of human hepatic stimulator substance. The translated human hepatic stimulator substance is a heat-, acid- and alkaline-resistant, but specific hepatic-stimulating, protein with a molecular weight in the range of 10 to 30 kD and with secreting ability. The characteristics of the translated human hepatic stimulator substance are consistent with those of biochemically purified human hepatic stimulator substance from human fetal liver cells. These results demonstrate that human hepatic stimulator substance is a product of gene expression of human fetal liver cells and that the complementary DNA of human hepatic stimulator substance could be screened from the complementary DNA library of human fetal liver tissue. (HEPATOLOGY 1993;17:225–229.)
Re: Andrew J. Stephenson, Michel Bolla, Alberto Briganti, et al. Postoperative Radiation Therapy for Pathologically Advanced Prostate Cancer After Radical Prostatectomy. Eur Urol 2012;61:443–51
Authors: Matthew R. Sydes, Claire Vale, Andrew Kneebone, Maria Pearse, Pierre Richaud, Jayne F. Tierney, Christopher C. Parker
Journal: European Urology (2012)
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Authors: Scott M. Grundy, James I. Cleeman, C. Noel Bairey Merz, H. Bryan Brewer, Luther T. Clark, Donald B. Hunninghake, Richard C. Pasternak, Sidney C. Smith, Neil J. Stone
Journal: Journal of the American College of Cardiology (2004)
Phase 3 randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2-<i>BRCA</i>-associated locally advanced or metastatic breast cancer (BC).
Authors: Shannon Puhalla, Hyo S. Han, Véronique Diéras, Michael Friedlander, George Somlo, Banu Arun, Hans Wildiers, Bella Kaufman, Jean-Pierre M. Ayoub, Melissa Shan, David Burmedi, Qin Qin, Jane Qian, Vincent L. Giranda, Stacie Peacock Shepherd
Journal: Journal of Clinical Oncology (2015)

TPS1102 Background: BRCA-mutated tumors are more susceptible to platinum therapy and PARP inhibitors due to underlying defects in homologous recombination repair of DNA damage. In preclinical models the potent oral PARP1/2 inhibitor veliparib was shown to enhance sensitivity to C and to have single-agent activity in BRCA+ cell lines. Phase 1 trials suggest promising antitumor activity and acceptable toxicity of veliparib plus C/P in triple-negative BC (Puhalla et al. Cancer Res 2012;72[24 suppl]:PD09-06) and single-agent activity of veliparib in BRCA+ BC (Somlo et al. J Clin Oncol 2014;32[15 suppl]:abstr. 1021). This phase 3 trial assesses efficacy and toxicity of veliparib plus C/P vs C/P alone in patients with HER2− BRCA-associated locally advanced or metastatic BC (NCT02163694). Methods: Phase 3 randomized, double-blind, placebo-controlled, multicenter trial. Eligible patients (female or male; ≥ 18 years) have HER2−metastatic/locally advanced unresectable BC with (suspected) deleterious BRCA1/2 germline mutations and received 2 or fewer prior lines of DNA-damaging chemotherapy for metastatic BC. In addition, patients must have received ≤ 1 prior line of platinum therapy (any setting) without progression within 12 months of completing treatment. Patients are randomized 2:1 to C/P with veliparib or C/P with placebo, stratified by estrogen and/or progesterone receptor expression, prior platinum therapy, and central nervous system metastases. Veliparib (120 mg p.o. BID) or placebo will be given on Days −2 to 5, C (AUC 6 mg/mL/min i.v.) on Day 1, and P (80 mg/m2 i.v.) on Days 1, 8, and 15 (21-day cycles). Treatment continues until unacceptable toxicity or progressive disease (PD). Patients in the placebo arm who discontinue due to PD are eligible for crossover to veliparib monotherapy. The primary objective is to assess if the addition of veliparib to C/P increases progression-free survival; additional objectives include evaluation of overall survival, clinical benefit rate, objective response rate, quality of life, and safety. Enrollment began in July 2014 with a planned sample size of 270 patients. Clinical trial information: NCT02163694.
LONGEVITY IN IRELAND.
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Conditions influencing release of granule contents from human platelets in citrated plasma induced by ADP or the thrombin receptor activating peptide SFLLRN: Direct measurement of percent release of β‐thromboglobulin and assessment by flow cytometry of P‐selectin expression
Authors: Margaret L. Rand, Dennis W. Perry, Marian A. Packham, Cynthia H. Gemmell, Erik L. Yeo, Raelene L. Kinlough‐Rathbone
Journal: American Journal of Hematology (1996)

Contrary to a recent report [Rinder et al.: Blood 82:505, 1993], aspirin does inhibit the release of α-granule contents as well as inhibiting the release of dense granule contents by human platelets during ADP-induced aggregation in citrated platelet-rich plasma (PRP). Measurements were: percent release of 14C-serotonin from prelabeled platelets, radio-immunoassay of β-thromboglobulin (βTG), and expression on the platelet surface of the α-granule constituent, P-selectin, by flow cytometry. During the second phase of ADP-induced aggregation, 69.0 ± 8.3% of βTG and 54.1 ± 4.6% of 14C-serotonin were released (means ± SEM, n = 13); aspirin treatment reduced these values to 6.0 ± 1.2 and 1.0 ± 0.3%, respectively. In contrast, incubation of platelets with ADP without stirring caused only 6.7 ± 1.7% release of βTG and 2.1 ± 0.4% release of 14C-serotonin; these low values were not appreciably affected by aspirin. During ADP-induced primary aggregation in PRP anticoagulated with FPRCH2Cl (PPACK), only 4.7 ± 0.9% release of βTG and no detectable release of 14C-serotonin occurred; aspirin had no effect. In both stirred and unstirred PRP, the thrombin receptor activating peptide, SFLLRN (50 μM), caused at least 75% release of the contents of both granules, which was partially inhibited by aspirin. Upon incubation of platelets with ADP (2–10 μM), the mean fluorescence intensity due to P-selectin was <14% of that induced by SFLLRN. In this unstirred system used for flow cytometry, aspirin treatment caused no significant inhibition of P-selectin expression. Thus, under conditions in which ADP does not cause secondary aggregation (physiological Ca2??? concentration or unstirred citrated PRP) release of the contents of both types of granules is less than 7% and aspirin is not inhibitory; the P-selectin expression associated with this low percent release is also unaffected by aspirin. However, aspirin does strongly inhibit the extensive release of both α-granule and dense granule contents during ADP-induced secondary aggregation in citrated PRP. © 1996 Wiley-Liss, Inc.
Gastroenterology
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Rabies in a Liama—Oklahoma
Journal: JAMA (1990)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal